At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 369 enrolled
Drug / intervention
PAZOPANIB +1 moredrug
Likely dose
PAZOPANIB 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
In Brief
A Phase 3 clinical trial evaluating PAZOPANIB and Placebo for Sarcoma, Soft Tissue. Completed, enrolled 369 participants across 81 sites in 13 countries.
Detailed Summary
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Soft Tissue
CountriesAustralia, Belgium, Denmark, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionNov 2010
Study CompletionDec 2012
TodayJul 2026
First PostedSep 16, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.8 years ago
Interventions
PAZOPANIBdrug
800 mg once daily orally
Placebodrug
matching placebo 800 mg once daily orally